Basic pharmacology of esmolol

https://doi.org/10.1016/0002-9149(85)90910-5Get rights and content

Abstract

Preclinical studies show that esmolol is an ultrashort-acting, cardioselective β blocker that possesses minimal partial agonist action or membrane-depressant properties. The electrophysiologic and hemodynamic actions of esmolol are the result of β blockade. No direct, β receptor-independent cardiovascular actions have been identified with β-blocking doses in laboratory experiments. Because esmolol slows atrioventricular conduction, increases atrioventricular refractoriness and decreases the determinants of myocardial oxygen demand, it should have use in the treatment of supraventricular tachycardias and acute myocardial ischemia. Esmolol, because of its ultrashort duration of action, should be safe for the induction of β blockade in patients who are critically ill and is ideally suited for rapidly changing levels of β blockade in this clinical situation.

References (29)

  • S. Yusuf et al.

    Reduction in infarct size, arrhythmias and chest pain by early intravenous beta-blockade in suspected acute myocardial infarction

    Circulation

    (1983)
  • Reduction of infarct size with the early use of timolol in acute myocardial infarction

    N Engl J Med

    (1984)
  • Effect of propranolol on myocardial-infarct size in a randomized blended multicenter trial

    N Engl J Med

    (1984)
  • G.S. May

    A review of acute phase beta-blocker trials in patients with acute myocardial infarction

    Circulation

    (1983)
  • Cited by (0)

    View full text